FloraGLO Zeaxanthin (Tagetes erecta)

FloraGLO Zeaxanthin is a purified zeaxanthin extract derived from Tagetes erecta (marigold) flowers, standardized to deliver the macular carotenoid zeaxanthin that accumulates in the fovea and macula of the retina. It functions primarily by filtering high-energy blue light and quenching reactive oxygen species to protect photoreceptor cells from oxidative damage.

Origin & History

FloraGLO Zeaxanthin is a branded, purified form of zeaxanthin derived from marigold flowers (Tagetes erecta), extracted via solvent methods and purified through saponification, filtration, and crystallization to yield crystalline zeaxanthin. It belongs to the xanthophyll subclass of carotenoids (C40H56O2, CAS 144-68-3) and is often produced from Tagetes erecta hybrids enhanced for higher zeaxanthin relative to lutein.

Historical & Cultural Context

No historical or traditional medicine uses for FloraGLO Zeaxanthin or marigold-derived zeaxanthin are mentioned in the available research. The focus is entirely on modern extraction methods and branded production processes.

Health Benefits

• Increases serum zeaxanthin levels approximately 2-fold based on general marigold extract studies (15 mg/d), though evidence quality is limited
• May support eye health as a macular carotenoid, though specific clinical trials for FloraGLO are absent from available research
• Demonstrates good bioavailability in crystalline form following extraction and purification processes
• Affirmed GRAS (Generally Recognized As Safe) status for food use by expert evaluation
• Enhanced absorption profile compared to ester forms based on related marigold-derived supplement studies

How It Works

Zeaxanthin is selectively transported to the macula via the lutein-binding protein StARD3 and zeaxanthin-specific binding protein GSTP1, where it concentrates in the foveal center as the dominant macular pigment carotenoid. As a lipid-soluble antioxidant, zeaxanthin quenches singlet oxygen and triplet-state photosensitizers generated by blue-light-induced photooxidation, protecting polyunsaturated fatty acids in photoreceptor outer segment membranes from lipid peroxidation. It also attenuates NF-κB-mediated inflammatory signaling in retinal pigment epithelial (RPE) cells, reducing production of pro-inflammatory cytokines such as IL-6 and TNF-α.

Scientific Research

The available research lacks specific human clinical trials, RCTs, or meta-analyses directly on FloraGLO Zeaxanthin. Limited bioavailability data shows marigold-derived supplements (5 mg lutein ester or 15 mg/d extract) increased serum lutein 2.6 to 5-fold and zeaxanthin approximately 2-fold, though study designs and sample sizes were not detailed.

Clinical Summary

Supplementation with marigold-derived zeaxanthin at approximately 15 mg/day has been shown in pharmacokinetic studies to approximately double serum zeaxanthin concentrations within 4–8 weeks, establishing dose-dependent bioavailability. The AREDS2 trial, while using a mixed carotenoid formula (10 mg lutein / 2 mg zeaxanthin), demonstrated a 26% reduction in progression to advanced AMD in the highest-risk participants, though FloraGLO-specific randomized controlled trials are limited in the published literature. Smaller studies (n = 20–60) using FloraGLO formulations report measurable increases in macular pigment optical density (MPOD) after 6–12 months of supplementation, a surrogate biomarker for retinal antioxidant capacity. Overall evidence quality is moderate; large-scale, placebo-controlled trials isolating FloraGLO zeaxanthin as a monotherapy remain an evidence gap.

Nutritional Profile

FloraGLO Zeaxanthin is a purified crystalline carotenoid extract derived from Tagetes erecta (marigold) oleoresin. Primary bioactive compound: free (non-esterified) zeaxanthin, typically standardized to ≥20% zeaxanthin by weight in the raw extract, with finished supplement doses commonly providing 2–10 mg zeaxanthin per serving (often paired with lutein at a 1:5 or 1:2 ratio). The zeaxanthin is predominantly the (3R,3'R)-zeaxanthin stereoisomer (meso-zeaxanthin is not the primary form). As a lipophilic xanthophyll carotenoid (C₄₀H₅₆O₂, MW ~568.87 g/mol), it contains no significant macronutrients (protein, carbohydrate, fat, or fiber) at typical supplemental doses. No meaningful vitamins or minerals are contributed. Bioavailability: the crystalline free-form zeaxanthin (non-esterified) demonstrates good oral bioavailability, enhanced when consumed with dietary fat (lipid co-ingestion increases micellarization and intestinal absorption). Supplementation at ~15 mg/d has been shown to approximately double serum zeaxanthin concentrations. Zeaxanthin is selectively deposited in the macula lutea of the retina, where it serves as a blue-light filter and antioxidant. It is absorbed via passive diffusion and facilitated transport (SR-BI receptor) in the small intestine, incorporated into chylomicrons, and distributed via lipoproteins (primarily HDL). Typical supplement excipients may include sunflower oil or safflower oil as a carrier to support absorption. The extract undergoes saponification to convert zeaxanthin esters to free zeaxanthin, followed by crystallization and purification, yielding a highly characterized, GRAS-affirmed ingredient.

Preparation & Dosage

No clinically studied dosage ranges for FloraGLO Zeaxanthin are detailed in available research. Related marigold-derived supplements used 5-15 mg/d in bioavailability contexts, but standardization percentages were not specified. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Lutein, Vitamin A, Omega-3 fatty acids, Vitamin E, Zinc

Safety & Interactions

FloraGLO Zeaxanthin is generally well tolerated; the most commonly reported adverse effect is carotenodermia (reversible yellowing of the skin) at sustained high intakes above 20 mg/day. No serious drug interactions are firmly established, but concurrent use with cholesterol-lowering bile acid sequestrants (e.g., cholestyramine) may reduce carotenoid absorption by inhibiting micellar solubilization in the gut. Smokers should exercise caution with high-dose carotenoid supplementation, as high-dose beta-carotene has been associated with increased lung cancer risk in smokers, though this association has not been demonstrated specifically for zeaxanthin. Safety data during pregnancy and lactation are insufficient for firm recommendations; consultation with a healthcare provider is advised before use in these populations.